Summary of Purpose
To describe the treatment perception from patients with non-valvular atrial fibrillation (NVAF) receiving Pradaxa® or VKA for stroke prevention by using the self-estimation questionnaire of PACT-Q during a 6-month study period.Read More →
The following dates are available for this trial. Trial information last updated on 5 March 2018.
|20 Jun 2017||13 Jun 2017||9 Aug 2018||29 Mar 2019||1 Mar 2018||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Boehringer Ingelheim Lead
- Boehringer Ingelheim